Sugi Predict

Sugi Predict / Compounds / SCHEMBL2833079

SCHEMBL2833079

SCHEMBL2833079

O=C(O)c1ncnc2ccccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ MAPT P10636 2/20 0.52
▸ ALDH1A1 P00352 2/20 0.52
▸ ADORA2A P29274 2/20 0.50
▸ ADORA3 P0DMS8 1/20 0.50
▸ PI4KA P42356 1/20 0.48
▸ PI4K2B Q8TCG2 1/20 0.48
▸ PI4K2A Q9BTU6 1/20 0.48
▸ PI4KB Q9UBF8 1/20 0.48
▸ PDE4A P27815 1/20 0.48
▸ PDE4B Q07343 1/20 0.48
▸ PDE4C Q08493 1/20 0.48
▸ PDE4D Q08499 1/20 0.48
▸ LMNA P02545 1/20 0.47
▸ BCAT2 O15382 1/20 0.46
▸ EGFR P00533 2/20 0.46
▸ DAPK3 O43293 1/20 0.46
▸ MAP4K4 O95819 1/20 0.46
▸ ABL1 P00519 1/20 0.46
▸ ERBB2 P04626 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30902246 1.00 SMN1; SMN2 (0.52) SMN1; SMN2MAPTALDH1A1ADORA2AADORA3
SCHEMBL31385237 0.82 PI4KA (0.52) SMN1; SMN2MAPTALDH1A1ADORA2AADORA3
SCHEMBL17099640 0.82 PI4KA (0.52) SMN1; SMN2MAPTALDH1A1ADORA2AADORA3
Lithium Ion SCHEMBL21818896 0.82 PI4KA (0.47) SMN1; SMN2MAPTALDH1A1ADORA2AADORA3
SCHEMBL28607066 0.80 ADORA2A (0.50) SMN1; SMN2MAPTALDH1A1ADORA2AADORA3
SCHEMBL27874136 0.79 PI4KA (0.44) SMN1; SMN2MAPTALDH1A1ADORA2AADORA3
SCHEMBL15500822 0.78 RXFP1 (0.51) SMN1; SMN2MAPTALDH1A1ADORA3LMNA
SCHEMBL16664897 0.78 RAB9A (0.50) MAPTALDH1A1ADORA3PI4KAPI4K2B
SCHEMBL15500953 0.78 LMNA (0.47) SMN1; SMN2MAPTALDH1A1ADORA2AADORA3
SCHEMBL21834591 0.77 KMT2A (0.56) MAPTALDH1A1ADORA2AADORA3PI4KA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100151684-A1 SLURRY COMPOSITION FOR PRIMARY CHEMICAL MECHANICAL POLISHING AND CHEMICAL MECHANICAL POLISHING METHOD LG CHEM LTD. (KR) 2010-06-17 — — US claimed
EP-2124949-A1 PHARMACEUTICAL FORMULATION Avera Pharmaceuticals, Inc. (US) 2009-12-02 — — EP claimed
WO-2008103914-A1 PHARMACEUTICAL FORMULATION AVERA PHARMACEUTICALS, INC. (US) 2008-08-28 — — WO claimed
US-4639454-A LYMPHOID LEUKEMIA E. I. DU PONT DE NEMOURS AND COMPANY (US) 1987-01-27 — — US claimed
EP-3856179-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-05-13 — — EP disclosed
US-20240327410-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2024-10-03 — — US disclosed
CN-113164458-B Monoacylglycerol lipase modulators 詹森药业有限公司 2024-09-13 — — CN disclosed
US-11993601-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV 2024-05-28 — — US disclosed
US-20230242531-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-08-03 — — US disclosed
US-11597728-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-03-07 — — US disclosed
US-20220315583-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2022-10-06 — — US disclosed
EP-3856179-A1 MONOACYLGLYCEROL LIPASE MODULATORS Janssen Pharmaceutica N.V. (BE) 2021-08-04 — — EP disclosed
WO-2002099097-A1 NOVEL COMPOUNDS FOR CHEMILUMINESCENSE PROCEDURES ROCHE DIAGNOSTICS GMBH (DE) 2002-12-12 — — WO disclosed
WO-2002099428-A1 LUCIFERIN HYDRAZIDES ROCHE DIAGNOSTICS GMBH (DE) 2002-12-12 — — WO disclosed
US-20020156050-A1 Carboxamine compounds, methods and compositions for inhibiting PARP activity GUILFORD PHARMACEUTICALS INC. 2002-10-24 — — US disclosed
US-6395749-B1 Carboxamide compounds, methods, and compositions for inhibiting PARP activity GUILFORD PHARMACEUTICALS INC. 2002-05-28 — — US disclosed
CN-1066445-C Aroyl-piperidine derivatives NOVARTIS AG (CH) 2001-05-30 — — CN disclosed
US-5965562-A TREATING DISORDERS INDUCED BY SUBSTANCE P AND MIGRAINE HEADACHE NOVARTIS CORPORATION (US) 1999-10-12 — — US disclosed
CN-1133839-A Aroyl-piperidine derivatives CIBA GEIGY AG (CH) 1996-10-23 — — CN disclosed
US-4639454-A LYMPHOID LEUKEMIA E. I. DU PONT DE NEMOURS AND COMPANY (US) 1987-01-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242531-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP SMN1; SMN2 3714/4885MAPT 2188/4885ALDH1A1 344/4885
US-20020156050-A1 Carboxamine compounds, methods and compositions for inhibiting PARP activity PARP1, PARP3, PARP4 SMN1; SMN2 4291/4885MAPT 4191/4885ALDH1A1 541/4885
US-11993601-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP SMN1; SMN2 3714/4885MAPT 2188/4885ALDH1A1 344/4885
US-11597728-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP SMN1; SMN2 3714/4885MAPT 2188/4885ALDH1A1 344/4885
US-20240327410-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP SMN1; SMN2 3714/4885MAPT 2188/4885ALDH1A1 344/4885
US-20220315583-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP SMN1; SMN2 3714/4885MAPT 2188/4885ALDH1A1 344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.